Before starting
Required
- Baseline
- Full blood count
- Liver function tests
- Serum creatinine (for creatinine clearance) or Estimated glomerular filtration rate
- Urea and electrolytes
- Urine dipstick
Continued until stable
Required
- 14 days after starting; then at 4, 8, and 12 weeks; then 3 monthly
- Full blood count
- Liver function tests
- Serum creatinine (for creatinine clearance) or Estimated glomerular filtration rate
- Urea and electrolytes
- Urine dipstick
Ongoing once stable
Required
- Every 6 months or annually (dependent on risk factors)
- Full blood count
- Liver function tests
- Urea and electrolytes
- Urine dipstick
- Every 6 months for first 4 years; then annually
- Serum creatinine (for creatinine clearance) or Estimated glomerular filtration rate
Abnormal results
Renal function
Stop if deteriorates.
Liver function
If AST or ALT are greater than twice the upper limit of the reference range, stop and discuss with specialist.
Notes
Haematological investigations
Perform haematological investigations if patient develops unexplained bleeding, bruising, purpura, anaemia, fever or sore throat.
Stop if suspicion or evidence of blood dyscrasia.
Bibliography
- Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press [cited 17/09/2020]
- Tillotts Pharma UK Limited. Summary of Product Characteristics – Octasa 400 mg modified-release tablets. Last revised 01/2021 [cited 17/09/2020]
- NICE Clinical Knowledge Summaries (CKS). Ulcerative colitis. Updated August 2020 [cited 21/09/2020]
- Lamb CA, Kennedy NA, Raine T et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68:s1-s107 [cited 30/07/2020]
- David S, Hamilton J. Drug-induced liver injury. US Gastroenterol Hepatol Rev. 2010 Jan 1; 6: 73–80 [cited 30/07/2020]